The Biotech Brief brings you clear, concise updates on the most impactful developments in biotechnology, precision medicine, and life science innovation. Produced by The HEII (Hub for Empowering Impactful Initiatives), this podcast breaks down clinical trial wins, regulatory shifts, and emerging therapeutic strategies in a format designed for busy scientists, entrepreneurs, investors, and changemakers. If you’re new to following the industry, this podcast is also for you. Stay informed. Stay inspired. Stay briefed.
All content for The Biotech Brief is the property of The HEII and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
The Biotech Brief brings you clear, concise updates on the most impactful developments in biotechnology, precision medicine, and life science innovation. Produced by The HEII (Hub for Empowering Impactful Initiatives), this podcast breaks down clinical trial wins, regulatory shifts, and emerging therapeutic strategies in a format designed for busy scientists, entrepreneurs, investors, and changemakers. If you’re new to following the industry, this podcast is also for you. Stay informed. Stay inspired. Stay briefed.
2: Twice the Targets, A Newly Approved Bispecific Enters the Myeloma Arena
The Biotech Brief
4 minutes 49 seconds
4 months ago
2: Twice the Targets, A Newly Approved Bispecific Enters the Myeloma Arena
Regeneron has officially entered the multiple myeloma arena with FDA approval of Lynozyfic, a BCMA-targeted bispecific antibody for patients who’ve exhausted standard therapies. In this episode, we break down what Lynozyfic is, how it works, and how it stacks up against competitors.
The Biotech Brief
The Biotech Brief brings you clear, concise updates on the most impactful developments in biotechnology, precision medicine, and life science innovation. Produced by The HEII (Hub for Empowering Impactful Initiatives), this podcast breaks down clinical trial wins, regulatory shifts, and emerging therapeutic strategies in a format designed for busy scientists, entrepreneurs, investors, and changemakers. If you’re new to following the industry, this podcast is also for you. Stay informed. Stay inspired. Stay briefed.
